Compare BDL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDL | MAIA |
|---|---|---|
| Founded | 1959 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 79.0M |
| IPO Year | 1995 | 2022 |
| Metric | BDL | MAIA |
|---|---|---|
| Price | $41.60 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.9K | ★ 502.3K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 49.72 | 33.33 |
| EPS | ★ 1.98 | N/A |
| Revenue | ★ $205,248,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.09 | ★ N/A |
| Revenue Growth | ★ 8.99 | N/A |
| 52 Week Low | $26.33 | $0.87 |
| 52 Week High | $47.99 | $3.19 |
| Indicator | BDL | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 54.32 |
| Support Level | $29.15 | $1.38 |
| Resistance Level | $47.99 | $1.46 |
| Average True Range (ATR) | 3.02 | 0.06 |
| MACD | 0.26 | 0.02 |
| Stochastic Oscillator | 64.66 | 69.64 |
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.